157 related articles for article (PubMed ID: 33304848)
21. A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.
Shimokawa M; Hasegawa S; Fukuoka K; Okada M; Yokoi K; Tanaka F; Yamanaka T; Daimon T; Nakano T
Jpn J Clin Oncol; 2013 May; 43(5):575-8. PubMed ID: 23509402
[TBL] [Abstract][Full Text] [Related]
22. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
Rimner A; Zauderer MG; Gomez DR; Adusumilli PS; Parhar PK; Wu AJ; Woo KM; Shen R; Ginsberg MS; Yorke ED; Rice DC; Tsao AS; Rosenzweig KE; Rusch VW; Krug LM
J Clin Oncol; 2016 Aug; 34(23):2761-8. PubMed ID: 27325859
[TBL] [Abstract][Full Text] [Related]
23. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
24. A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study.
Vicidomini G; Della Corte CM; Noro A; Di Liello R; Cappabianca S; Fiorelli A; Nardone V; Messina G; Viscardi G; Sangiovanni A; Monti R; Accardo M; Morgillo F; Ciardiello F; Franco R; Santini M
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008306
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
Ou W; Li N; Wang SY; Li J; Liu QW; Huang QA; Wang BX
Cancer; 2016 Mar; 122(5):740-7. PubMed ID: 26700505
[TBL] [Abstract][Full Text] [Related]
26. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
27. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
[TBL] [Abstract][Full Text] [Related]
28. Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
Hasegawa S; Kondo N; Matsumoto S; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Kamikonya N; Tsujimura T; Nakano T
Semin Thorac Cardiovasc Surg; 2019; 31(2):301-309. PubMed ID: 30639549
[TBL] [Abstract][Full Text] [Related]
29. Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Infante M; Morenghi E; Bottoni E; Zucali P; Rahal D; Morlacchi A; Ascolese AM; De Rose F; Navarria P; Crepaldi A; Testori A; Voulaz E; Errico V; Perrino M; Scorsetti M; Chiti A; Santoro A; Alloisio M
Eur J Cardiothorac Surg; 2016 Dec; 50(6):1077-1082. PubMed ID: 27330149
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
Nelson DB; Rice DC; Niu J; Atay S; Vaporciyan AA; Antonoff M; Hofstetter WL; Walsh GL; Swisher SG; Roth JA; Tsao A; Gomez D; Giordano SH; Mehran R; Sepesi B
J Clin Oncol; 2017 Oct; 35(29):3354-3362. PubMed ID: 28817374
[TBL] [Abstract][Full Text] [Related]
31. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
Rosenzweig KE; Zauderer MG; Laser B; Krug LM; Yorke E; Sima CS; Rimner A; Flores R; Rusch V
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1278-83. PubMed ID: 22607910
[TBL] [Abstract][Full Text] [Related]
32. Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience.
Mangiameli G; Bottoni E; Voulaz E; Cariboni U; Testori A; Crepaldi A; Giudici VM; Morenghi E; Alloisio M
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768488
[TBL] [Abstract][Full Text] [Related]
33. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818
[TBL] [Abstract][Full Text] [Related]
34. A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.
Pasello G; Altavilla G; Bonanno L; Rea F; Favaretto AG
J Thorac Dis; 2010 Dec; 2(4):254. PubMed ID: 22263055
[TBL] [Abstract][Full Text] [Related]
35. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
37. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
38. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.
Kostron A; Friess M; Inci I; Hillinger S; Schneiter D; Gelpke H; Stahel R; Seifert B; Weder W; Opitz I
Interact Cardiovasc Thorac Surg; 2017 May; 24(5):740-746. PubMed ID: 28453802
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
40. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
